Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...
The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...
– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...
STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results